Researchers can already grow organ-like tissues and some replacement skin, but building a full-sized kidney, heart or liver ready for transplantation remains a far greater challenge.
THE UNIVERSAL RECORD
Sourced reporting. No opinions.
Brad Socha | August 26, 2026 | 5:17 AM EST
A functioning human organ begins with cells, but recreating one outside the body requires far more than simply growing enough of them. Scientists must reproduce intricate structures containing multiple cell types, blood vessels, connective tissue and, in some organs, nerves and drainage systems, then ensure everything continues working after transplantation.
That challenge is driving rapid progress in organoids, stem-cell biology, tissue engineering and 3D bioprinting. Researchers can now create miniature structures that reproduce important features of kidneys, hearts, livers, intestines and other organs. Some engineered human tissues have already reached patients. Yet scientists cannot currently manufacture a complete, full-sized replacement heart, kidney or liver for routine human transplantation.
The distinction matters. A laboratory structure that behaves like part of an organ is not necessarily an organ capable of replacing one.
Organoids Are Bringing Scientists Closer
Organoids are small, three-dimensional collections of cells that self-organize and reproduce selected aspects of an organ’s structure and function. They can be created from stem cells or other cells and have become increasingly valuable for studying human development, disease and potential treatments.
The National Institutes of Health describes organoids as lab-grown models capable of mimicking characteristics of human organs. Researchers have developed organoids representing tissues including the brain, intestine, lung, kidney and liver.
Stem cells are central to much of this work because certain types can develop into specialized cells. Induced pluripotent stem cells are particularly significant: adult cells can be reprogrammed into a pluripotent state and then directed toward different cell types. In principle, cells originating from a patient could eventually help produce personalized replacement tissue.
Another approach is 3D bioprinting. Rather than printing plastic or metal, specialized systems can deposit living cells, biomaterials and biological factors in carefully controlled arrangements. Combining bioprinting with organoids could give researchers greater control over tissue architecture while retaining the cells’ ability to organize themselves.
There is already a major difference between what can be produced experimentally and what can be transplanted as a replacement organ.
Skin demonstrates how far regenerative medicine has progressed. The U.S. Food and Drug Administration permits the use of Epicel, cultured epidermal autografts made by expanding a patient’s own skin cells, for certain patients with extensive deep dermal or full-thickness burns. These grafts replace the epidermal layer rather than recreating every component of natural skin, but they show that laboratory-expanded human tissue can have direct clinical applications.
Solid organs present a much harder engineering problem.
Kidney organoids can develop structures resembling nephrons, the functional units involved in filtering blood. Research has shown that transplantation into experimental animals can promote vascularization and maturation. However, kidney organoids remain immature compared with adult kidneys, and creating the specialized vascular network and a functional route for urine to leave engineered tissue remain major obstacles.
Heart research faces different requirements. Engineered cardiac cells and tissues can contract, providing models for studying heart development, disease and drugs. But a replacement heart would need billions of appropriately organized cells, chambers, valves, electrical conduction, coronary circulation and sufficient mechanical strength to pump continuously under pressure.
The liver’s regenerative properties offer another route. In research highlighted by the NIH in May 2026, scientists demonstrated a method for controlling the growth of engineered human liver tissue after implantation in mice. The proof-of-concept study suggests that instead of manufacturing an entire organ before implantation, future therapies might implant smaller engineered tissues capable of expanding inside the body. The approach remains experimental and has not established a replacement for human liver transplantation.
Why Growing a Full Organ Is So Difficult
Blood supply is among the greatest obstacles. Cells need oxygen and nutrients, and simple diffusion can support only relatively small amounts of tissue. A human-sized organ therefore requires an extensive network of vessels capable of carrying blood into microscopic regions while removing waste.
Scientists are making progress. NIH-supported researchers reported in 2025 that they created lung and intestinal organoids capable of developing specialized blood vessels. Nevertheless, recreating the hierarchical vascular systems of full-sized organs remains a major bioengineering challenge.
Size is only part of the problem. Cells must appear in the right places, mature into appropriate types and communicate with one another. An engineered kidney must filter blood and process the filtrate. A heart must synchronize electrical activity with mechanical contraction. Liver tissue must perform numerous metabolic and synthetic functions while interacting with the circulation and bile system.
Then comes transplantation.
A donated organ can trigger an immune response because the recipient’s body recognizes it as foreign. Transplant patients therefore commonly require immunosuppressive treatment. Tissue produced from a patient’s own cells could potentially reduce some immune incompatibility, but personalized cells do not automatically eliminate every safety or immune problem. Manufacturing processes, mutations, incomplete cell differentiation and other biological factors must also be controlled.
Researchers must additionally demonstrate that engineered tissues remain safe and functional for years, not merely days or months. Production would have to be reproducible, sterile and scalable while meeting stringent regulatory standards.
That explains why the nearer-term impact of organ engineering may not look like a laboratory suddenly producing complete spare hearts or kidneys. Engineered tissues could instead repair damaged sections of organs, provide temporary support, restore particular functions or help patients remain stable while awaiting transplantation.
Organoids are already useful for modelling disease and testing treatments. Engineered skin has crossed into clinical care, while experimental kidney, cardiac and liver tissues continue to advance.
The long-term objective, a personalized, fully functional human organ grown when a patient needs one, remains scientifically plausible enough to drive intensive research, but significant biological and engineering barriers remain. The laboratory has learned to reproduce increasingly sophisticated pieces of human organs. Turning those pieces into durable, transplantable organs is the much harder step still ahead.
Sources:
National Institutes of Health — Organoid, NCATS Toolkit
https://toolkit.ncats.nih.gov/glossary/organoid/
National Institutes of Health — NIH Standardized Organoid Modeling Center
https://www.nih.gov/som
National Institutes of Health — Scientists Spur Growth of Implanted Liver Tissue
https://www.nih.gov/news-events/nih-research-matters/scientists-spur-growth-implanted-liver-tissue
National Institutes of Health — Scientists Create Organoids With Specialized Blood Vessels
https://www.nih.gov/news-events/nih-research-matters/scientists-create-organoids-specialized-blood-vessels
National Institutes of Health — Stem Cells and Regenerative Medicine
https://www.orip.nih.gov/division-comparative-medicine/initiatives/stem-cells-and-regenerative-medicine
U.S. Food and Drug Administration — Epicel (Cultured Epidermal Autografts)
https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/epicel-cultured-epidermal-autografts
PubMed — Challenges in Maturation and Integration of Kidney Organoids for Stem Cell-Based Renal Replacement Therapy
https://pubmed.ncbi.nlm.nih.gov/39571903/
Nature Reviews Bioengineering — Organoid Bioprinting: From Cells to Functional Tissues
https://www.nature.com/articles/s44222-024-00268-0
About the Author
Brad Socha is the founder of The Universal Record, focused on sourced, factual global reporting. Coverage includes international news, geopolitics, technology, and major developments.
